The clinical features and reproductive prognosis of ovarian neoplasms with hyperandrogenemia: a retrospective analysis of 33 cases

Gynecol Endocrinol. 2019 Sep;35(9):825-828. doi: 10.1080/09513590.2019.1599855. Epub 2019 Apr 16.

Abstract

The aim of this study is to review the natural course, clinical features, and reproductive prognosis of ovarian tumors associated with hyperandrogenemia. We retrospect 33 patients of ovarian tumors with hyperandrogenemia. Thirty cases (91%) were sex cord-stromal tumors. Sertoli-Leydig cell tumors, Leydig cell tumors, and steroid cell tumors were the most common types. It is not possible, to predict the pathological subtypes based on androgen levels alone. Most of these tumors were solid masses, with an average diameter of 3.9 cm. These tumors are soft or fragile, no clear boundary with normal tissue, thus excision is superior to exfoliation. The average disease course of the top three tumors was 32.6, 35.4, and 67.7 months, respectively. Among 11 married women with a desire to get pregnant, nine cases resumed menstrual periods after surgery and became pregnant naturally. Hyperandrogenemia might predict a better prognosis. The asynchronism of hyperandrogenemia and undetectable tumor may cause irreversible change and emotional depress, the methods of early diagnosis need further study.

Keywords: Hyperandrogenemia; acne; clinical features; clitoral hypertrophy; hirsutism; ovarian neoplasms.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Androgens / blood
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / metabolism
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Fertility Preservation
  • Humans
  • Hyperandrogenism / complications*
  • Hyperandrogenism / diagnosis*
  • Hyperandrogenism / pathology
  • Hyperandrogenism / surgery
  • Middle Aged
  • Ovarian Neoplasms / complications*
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery
  • Prognosis
  • Retrospective Studies
  • Sertoli-Leydig Cell Tumor / complications
  • Sertoli-Leydig Cell Tumor / diagnosis
  • Sertoli-Leydig Cell Tumor / pathology
  • Sertoli-Leydig Cell Tumor / surgery
  • Sex Cord-Gonadal Stromal Tumors / complications*
  • Sex Cord-Gonadal Stromal Tumors / diagnosis*
  • Sex Cord-Gonadal Stromal Tumors / pathology
  • Sex Cord-Gonadal Stromal Tumors / surgery
  • Tumor Burden
  • Young Adult

Substances

  • Androgens
  • Biomarkers, Tumor